Skip to content

Registry of Ehlers-Danlos Syndrome

Registry of Ehlers-Danlos Syndrome That Collects Clinical, Functional, Genetic, Genealogical, Imaging, Surgical, Treatment, Quality of Life Data. Data Are Linked to Patients' Biological Samples, When Available

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04133272
Acronym
RED
Enrollment
3000
Registered
2019-10-21
Start date
2014-06-30
Completion date
2033-01-31
Last updated
2025-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ehlers-Danlos Syndrome

Keywords

Disease Registry, Natural History Study, Disease Evolution, Genotype-Phenotype Correlation

Brief summary

RED is a retrospective and prospective registry, finalized for care and research purposes. It is articulated in main sections - strongly related and mutually dependent on each other - corresponding to different data domains: personal information, clinical data, genetic data, genealogical data, surgeries, etc. This approach has been developed to corroborate and integrate data from different sources and evaluating several aspects of diseases and to correlate genetic background and phenotypic outcomes, in order to better investigate disease pathophysiology. Due to legal requirements, institutional directives and organizational issues, we are unable to include individuals residing outside Italy in the registry at this time. We are currently engaged in the preparation of a recruitment process for individuals residing outside Italy.

Detailed description

The traditional method of collecting patient information is often chaotic, inconvenient and sometimes even unsafe, particularly when dealing with rare diseases. In 2014, the need to simplify the diagnostic process and to overcome the difficulties of data storage and analysis, led to the suggestion of implementing the Registry of Ehlers-Danlos Syndrome (RED). The RED relies on an IT platform named Genotype-phenotype Data Integration platform - GeDI. This solution was developed through a collaboration between Rare Skeletal Disease Department and a local software company (Dilaxia) and is General Data Protection Regulation (GDPR)-compliant, multi-client and web-accessible. It has been designed according to current medical informatics standards, including the Orphanet code, the International Classification of Diseases (ICD), the Human Genome Variants Society, aiming to follow FAIR (Findability Accessibility Interoperability Reusability) principles. GeDI is continuously being implemented to improve the management of people with Ehlers-Danlos Syndrome and to assist researchers in analysing the information collected. RED is divided into the following main sections: * Personal data: it comprises general information, birth details and residence data; * Patient data: including the patients internal code, the hospital code and other patient details; * Diagnostic Process: the diagnosis, the status (affected, suspected, etc.), age at diagnosis, comorbidities, allergies, etc.; * Genogram: a tool for designing the family transmission of the disease, alongside information on the disease status of all relatives included; * Clinical events: it records a long list of signs and symptoms of Ehlers-Danlos Syndrome as well as several additional items to describe the disease * Genetic Analysis and Alteration: including analytical technique, sample information, analysis duration, etc. This section also comprises detailed information on any detected pathological variants (e.g. gene, international reference, DNA change, protein change, genomic position, etc.); * Visits: this section includes visit type (genetic, orthopedic, rehabilitation, pediatric, etc.), the date of the visit, prescriptions, imaging, etc.; * Treatments: this section comprises information of a wide range of treatments including pharmacological, devices, supplements, and other treatments such as psychological, nutritional, etc.; * Surgeries: this section contains information on the type of surgeries, the age of the patients, the site/localization of the procedures, etc. * Documents: this repository allow us to store all types of documents (radiological reports, imaging, consents, clinical reports, etc.); * Consents: this section provides a comprehensive overview of all consents collected, including the collection date; * Samples: this section includes information on the samples, like the type, date of collection, etc. * PROs: this section collects information on patients reported outcomes such as the quality of life or ABC scale.

Interventions

None listed

Sponsors

Luca Sangiorgi
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* All Ehlers-Danlos Syndrome patients, including prenatal and fetal diagnosis of Ehlers-Danlos Syndrome

Exclusion criteria

* Any condition unrelated to Ehlers-Danlos Syndrome

Design outcomes

Primary

MeasureTime frameDescription
Natural History and Epidemiology in terms of clinical, genetic and functional evaluation25 yearsTo maintain an established registry in order to assess epidemiology and natural history. Collection of: 1. physical examinations data: assessment of type of the disease (according to Orphanet types) 2. orthopedic and functional data: stature (cm), weight (kg), Beighton score, pain score (numeric scale), presence cardiac lesion (ultrasound) 3. surgical procedures: type, number and site of surgeries disease-related and age at surgeries 4. genetics background: target gene, type of mutation, type of variant detected, clinical significance 5. family history: inheritance in maternal or paternal line 6. treatment information: pharmacological, devices, supplements, and other treatments Clinical, orthopedic, surgical, treatment and functional features are updated at each follow up. Clinical reports, medical charts, genetic report and imaging are the primary sources of data.

Secondary

MeasureTime frameDescription
Genotype-Phenotype Correlation among clinical features and molecular background25 yearsThe secondary outcome comprises the correlation between genotype and phenotype. This includes but is not limited to clinical features and genetic background. This will be pursued using the information collected during visits and follow-ups and the genetic information resulting from molecular investigations

Other

MeasureTime frameDescription
Longitudinal study of disease (including prospective and retrospective data)25 yearsThis outcome aims to investigate the Ehlers-Danlos Syndrome trend during time. This will be evaluated within the families and among the families. Main clinical features, such as height (cm), pain (numeric scale) and other variables will be collected both retrospectively and prospectively. An evaluation of these parameters will be performed at each visit to keep track on the progression of clinical manifestations.

Countries

Italy

Contacts

Primary ContactMarina Mordenti, PhD
registri.malattierare@ior.it+39 05 6366062
Backup ContactMarcella Lanza, PhD
registri.malattierare@ior.it+39 05 6366169

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026